** Shares of medical device maker Tivic Health Systems TIVC.O rise 232.6% to $11.82 premarket
** TIVC says it provided briefings at the White House and FDA which secured positive interest in potential military and defense applications for its biologic and bioelectronic product candidates
** Both meetings were held last week in Washington D.C. - TIVC
** Separately, co says it discussed the potential for expedited pathways and support for export opportunities for its lead experimental immunotherapy drug called entolimod
** Entolimod is being tested in a late-stage study in patients to treat acute radiation syndrome $(ARS.UK)$, a condition caused by exposure to high doses of ionizing radiation
** As of last close, TIVC had fallen 40.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。